S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:FUSN

Fusion Pharmaceuticals News Headlines

$4.00
+0.18 (+4.71%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$3.82
$4.08
50-Day Range
$3.82
$7.86
52-Week Range
$3.71
$10.40
Volume
3,900 shs
Average Volume
38,846 shs
Market Capitalization
$173.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.66
Get Fusion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Fusion Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FUSN
News Sentiment

0.53

0.48

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FUSN Articles
This Week

18

1

FUSN Articles
Average Week



Fusion Pharmaceuticals (NASDAQ:FUSN) News Headlines Today

SourceHeadline
MarketBeat logoFusion Pharmaceuticals Inc. (NASDAQ:FUSN) to Post Q1 2023 Earnings of ($0.46) Per Share, Wedbush Forecasts
americanbankingnews.com - May 13 at 3:42 AM
MarketBeat logoWedbush Lowers Fusion Pharmaceuticals (NASDAQ:FUSN) Price Target to $19.00
americanbankingnews.com - May 12 at 4:48 AM
seekingalpha.com logoFusion Pharmaceuticals GAAP EPS of -$0.46, revenue of $0.59M
seekingalpha.com - May 12 at 1:14 AM
finance.yahoo.com logoFusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day
finance.yahoo.com - May 11 at 8:13 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Program Updates
finance.yahoo.com - May 10 at 7:44 AM
finance.yahoo.com logoFusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 26 at 7:10 PM
MarketBeat logoFusion Pharmaceuticals (NASDAQ:FUSN) Rating Lowered to Hold at Zacks Investment Research
americanbankingnews.com - April 22 at 1:28 AM
finance.yahoo.com logoFurther weakness as Fusion Pharmaceuticals (NASDAQ:FUSN) drops 19% this week, taking one-year losses to 30%
finance.yahoo.com - April 20 at 1:23 PM
seekingalpha.com logoFusion Pharmaceuticals GAAP EPS of -$0.40 beats by $0.09, revenue of $0.6M
seekingalpha.com - March 17 at 4:49 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates
finance.yahoo.com - March 17 at 4:49 PM
finance.yahoo.com logoWe're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
finance.yahoo.com - February 19 at 1:13 PM
seekingalpha.com logoFusion Pharmaceuticals grants stock options to one employee
seekingalpha.com - February 9 at 1:20 PM
finance.yahoo.com logoFusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference
finance.yahoo.com - January 21 at 10:17 AM
seekingalpha.com logoFusion Pharma collaborates with Pepscan to develop peptide-based radiopharmaceuticals
seekingalpha.com - January 11 at 12:49 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals
finance.yahoo.com - January 11 at 12:49 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals
finance.yahoo.com - January 11 at 12:49 PM
seekingalpha.com logoFusion Pharmaceuticals announces nomination of first TAT candidate under AstraZeneca tie-up
seekingalpha.com - January 10 at 7:14 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZeneca to Advance into IND-Enabling Studies for Phase 1 Development
finance.yahoo.com - January 10 at 7:14 PM
nasdaq.com logoWhat Type Of Shareholders Make Up Fusion Pharmaceuticals Inc.'s (NASDAQ:FUSN) Share Registry?
nasdaq.com - December 24 at 1:59 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update
finance.yahoo.com - November 9 at 11:04 AM
finance.yahoo.com logoFusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer
finance.yahoo.com - November 2 at 7:32 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies
finance.yahoo.com - October 20 at 8:27 PM
finance.yahoo.com logoFusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer
finance.yahoo.com - September 28 at 10:25 PM
nasdaq.com logoHere's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
nasdaq.com - September 25 at 4:28 PM
finance.yahoo.com logoFusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
finance.yahoo.com - September 23 at 8:42 PM
finance.yahoo.com logoFusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Business Development
finance.yahoo.com - September 21 at 12:13 PM
finance.yahoo.com logoFusion Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 2 at 4:17 PM
finance.yahoo.com logoWe Think Fusion Pharmaceuticals (NASDAQ:FUSN) Can Afford To Drive Business Growth
finance.yahoo.com - August 23 at 3:24 PM
finance.yahoo.com logoFusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production
finance.yahoo.com - August 12 at 4:57 PM
barrons.com logoFusion Pharmaceuticals Inc.
barrons.com - August 11 at 10:54 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Update
finance.yahoo.com - August 10 at 8:29 AM
finance.yahoo.com logoFusion Pharmaceuticals to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference
finance.yahoo.com - August 5 at 7:22 PM
baystreet.ca logoFusion Warms to FDA Nod
baystreet.ca - July 29 at 1:25 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - July 7 at 12:53 PM
markets.businessinsider.com logoStock Alert: Fusion Pharma Jumps 15%
markets.businessinsider.com - June 15 at 5:28 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434
finance.yahoo.com - June 14 at 7:59 PM
finance.yahoo.com logoFusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research
finance.yahoo.com - June 7 at 6:32 PM
nasdaq.com logoFusion Pharmaceuticals Inks Manufacturing Deal with McMaster University
nasdaq.com - June 3 at 1:27 PM
finance.yahoo.com logoFusion Pharmaceuticals Enters into Agreement to Build Radiopharmaceutical Manufacturing Facility
finance.yahoo.com - June 2 at 12:54 PM
finance.yahoo.com logoFusion Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 27 at 5:32 PM
finance.yahoo.com logoWhat Kind Of Shareholders Hold The Majority In Fusion Pharmaceuticals Inc.'s (NASDAQ:FUSN) Shares?
finance.yahoo.com - May 25 at 12:30 PM
finance.yahoo.com logoFusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update
finance.yahoo.com - May 11 at 7:53 AM
finance.yahoo.com logoFusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study
finance.yahoo.com - May 6 at 4:57 PM
nasdaq.com logoFusion, Merck To Evaluate Fusion's Targeted Alpha Therapy In Combination With Merck's KEYTRUDA
nasdaq.com - May 6 at 11:57 AM
finance.yahoo.com logoFusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R
finance.yahoo.com - May 6 at 11:57 AM
finance.yahoo.com logoFusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 14 at 9:58 AM
benzinga.com logoMorgan Stanley Maintains Overweight on Fusion Pharmaceuticals, Lowers Price Target to $21
benzinga.com - April 7 at 2:02 PM
finance.yahoo.com logoFusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors
finance.yahoo.com - April 1 at 9:31 AM
finance.yahoo.com logoAre Insiders Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Stock?
finance.yahoo.com - March 26 at 9:42 AM
finance.yahoo.com logoFusion Pharmaceuticals Announces Fourth Quarter 2020 Financial Results and Business Update
finance.yahoo.com - March 25 at 8:14 AM
Get Fusion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for FUSN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.